Premium
Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients
Author(s) -
Yoshimura Reiji,
UmeneNakano Wakako,
Suzuki Akihito,
Ueda Nobuhisa,
Miyamoto Kyoko,
IkenouchiSugita Atsuko,
Hori Hikaru,
Otani Koichi,
Nakamura Jun
Publication year - 2009
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/hup.1043
Subject(s) - paroxetine , serotonin transporter , medicine , reuptake inhibitor , serotonin , depression (economics) , genotype , major depressive disorder , rating scale , hamilton rating scale for depression , gastroenterology , endocrinology , psychology , biology , receptor , gene , genetics , developmental psychology , economics , macroeconomics , amygdala
In the present study, we investigated the relationship between the serotonin transporter gene linked polymorphic regions (5‐HTTLPR) or plasma paroxetine levels and clinical response to paroxetine in depressed patients. Sixty patients who met the DSM‐IV criteria for major depressive disorder were enrolled in the study. Twenty‐two were male and 38 were female, with ages ranging from 25 to 71 (mean ± SD = 42 ± 16) years. The clinical improvement of patients was assessed using the Hamilton rating scale for depression (Ham‐D) before and every week after paroxetine administration. According to the data reported previously, patients with an at least 50% decrease in their Ham‐D score were classified as responders. The results showed that the plasma paroxetine levels at 4 weeks were significantly higher in responders (rapid responders) than in nonresponders. On the other hand, no significant associations were found between the L genotype (L/L, L/S) or S genotype (S/S) and the response rates either at 4 weeks or 8 weeks. These results suggest that patients with higher plasma levels at 4 weeks might respond rapidly to paroxetine treatment, but the final response rate at 8 weeks will be independent of the plasma paroxetine levels and the 5‐HTTLPR L/S genotype. Copyright © 2009 John Wiley & Sons, Ltd.